gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TELAHealthcareSurgical Instruments

TELA Bio, Inc. Common Stock (TELA)

$0.8378+4.46%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$0.80▼ 41.46% in range
Nov 3, 2025Low $0.56 · High $1.41Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

TELA Bio closed at $0.84 on Nov 4, up 4.46%, 40.6% below its 52-week closing high. Volume of 201.1K shares was 1.65× its 20-day average (above normal).

Split-adjusted performance: -23.1% over one month, -15.4% over six months, -38.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $19.29M, down 4.5% from a year earlier, with a net margin of -58.4%.

Short interest was 639.0K shares at the Oct 15 settlement, up 36.2% from the prior report (2.0% of float, 3.8 days to cover).

Market cap$37.8M45.1M shares
Revenue · quarter$19.3M−4.5% YoY
Diluted EPS$-0.20—
P/E · TTM—P/S 0.5×
Net margin-58.4%Gross 72.3%
Dividend yieldNone
52-week range0.56 – 1.41−40.6% from high
Volume201.1K1.65× 20-day avg
Volatility · 60d85.7%Annualised
Short % of float2.0%3.8 days to cover
Net cash-$25.7MCash $30.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −14.2%1M −23.1%3M −2.6%6M −15.4%YTD −29.0%1Y −38.8%3Y −85.6%5Y −93.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum40
Revenue growth15
Net margin30
Value (low P/E)—
Size28

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short639.0K+36.2% vs prior
Days to cover3.8Settled Oct 15
% of float2.0%
Short vol. 10d23.4%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TELATELA Bio$0.8378+4.46%−15.4%−4.5%−58.4%—$37.8M
NSPRInspireMD$0.7810+18.71%−32.7%−0.4%−808.8%—$36.6MCompare
NEPHNephros$3.25+0.31%+0.9%+36.2%19.9%20.3$35.3MCompare
XTNTXtant Medical Holdings$0.2960+6.47%−48.7%−35.0%−40.9%—$41.5MCompare
CVRXCVRx$1.58+14.49%−77.7%+15.6%−89.4%—$42.1MCompare
DRIODarioHealth$2.97−1.00%−62.8%−3.6%−153.1%0.0$29.1MCompare
MDAISpectral AI$1.53+2.00%−31.1%−30.4%−118.5%—$49.2MCompare
SNWVSANUWAVE Health$5.73−3.37%−64.0%−3.1%−7.0%3.4$49.3MCompare
DXRDaxor$8.91+2.44%−12.1%+2.3%−403.2%—$52.0MCompare

News about TELA Bio

All news →
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue ReinforcementGlobeNewswire Inc. · Oct 5, 2026▲ Positive

Quick answers

What does TELA Bio do?
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials.
What is TELA's market cap?
$37.82M, based on the Nov 4 close of $0.84.
Does TELA Bio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TELA is sold short?
639.0K shares, 2.0% of float, as of Oct 15, 2026.
What sector is TELA in?
Healthcare, in the Surgical Instruments industry.

About TELA Bio

TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

HQ: Malvern, PA218 employeesListed Nov 8, 2019telabio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology